Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)

(PRNewsfoto/Hanmi Pharmaceutical)

Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications

SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi") today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's biologic drug candidate sonefpeglutide (LAPSGLP-2 analog) with Eli Lilly and Company ("Lilly").

Recommended for you